A Study of NX-1607 in Adults With Advanced Malignancies
Recruiting Status:
Recruiting
Age:
18 Years+
Phase 1a will consist of 2 study arms: Monotherapy and Paclitaxel combo. Phase 1a dose escalation will evaluate the safety and tolerability of NX-1607 in adult patients with advanced solid tumors for which standard therapy with proven clinical benefit does not exist, is no longer effective, or is not appropriate. Indications for monotherapy include platinum […]
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting Status:
Recruiting
Age:
18 Years+
Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-5948 in adult patients with relapsed/refractory (R/R) B cell malignancies who have received at least 2 prior lines of therapy and for whom no other therapies are known to provide clinical benefit. Indications include: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), […]
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Recruiting Status:
Recruiting
Age:
18 Years+
Phase 1a is a dose escalation to evaluate the safety and tolerability of NX-2127 in adult patients with relapsed/refractory (R/R) B-cell malignancies, who have required and received at least 2 prior systemic therapies (or at least 1 prior therapy for patients with WM or PCNSL) and for whom no other therapies are known to provide […]
'